Clinical Trial Update: TH-302 in Combination With Bevacizumab for Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating TH-302 in combination with bevacizumab in glioblastoma has completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• TH-302 (evofosfamide)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Glioblastoma | Phase 2 | Status: COMPLETED | Results posted: 2020-04-10